EP Patent

EP3328867B1 — Crystalline form of lorlatinib free base

Assigned to Pfizer Inc · Expires 2020-11-11 · 6y expired

What this patent protects

Patent listed against Lorbrena.

Drugs covered by this patent

Lorbrena (lorlatinib) · Pfizer

Patent Metadata

Patent number: EP3328867B1
Jurisdiction: EP
Classification: —
Expires: 2020-11-11
Drug substance claim: No
Drug product claim: No
Assignee: Pfizer Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.